Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@MarketPulse360](/creator/twitter/MarketPulse360)
"Inspira Technologies Regains Nasdaq Compliance: Minimum Bid Price Achieved $IINN ➡ Inspira Technologies received notification from Nasdaq confirming compliance with the minimum bid price requirement. ➡ The company's common shares maintained a closing bid price at or above $XXXX per share for XX consecutive business days. ➡ According to the announcement Inspira's CEO Dagi Ben-Noon views this compliance as a reflection of market confidence in the company's strategic direction. ➡ Inspira is focusing on global distribution and execution leveraging achievements like a large commercial order and"  
![@MarketPulse360 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1517444811296587777.png) [@MarketPulse360](/creator/x/MarketPulse360) on [X](/post/tweet/1946192967980462470) 2025-07-18 12:58:56 UTC XX followers, XX engagements


"Dr. Reddy's Launches Sanofi's Beyfortus in India for RSV Prevention #DRREDDY $RDY ➡ Dr. Reddys Laboratories has launched Beyfortus (nirsevimab) in India a preventive treatment for Respiratory Syncytial Virus (RSV) in infants following an expanded partnership with Sanofi. ➡ RSV is a significant yet underreported health crisis in India causing many respiratory infections in infants with experts reporting over 2000 child deaths in 2024 from Kolkata Bengaluru and Mumbai alone. ➡ According to the Article Beyfortus launch aligns with Dr. Reddy's dual-track growth strategy strengthening its core"  
![@MarketPulse360 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1517444811296587777.png) [@MarketPulse360](/creator/x/MarketPulse360) on [X](/post/tweet/1945970502436020389) 2025-07-17 22:14:56 UTC XX followers, XX engagements


"BiomX's Phase 2b Trial Begins Analyst Reiterates $XX Target $PHGE ➡ BiomX initiated patient dosing in Phase 2b trial for BX004 targeting lung infections in cystic fibrosis patients. ➡ H.C. Wainwright reaffirmed a Buy rating and $XX price target for BiomX citing confidence in its dual-asset approach. ➡ Phase 1b/2a trial of BX004 showed XXXX% of patients completely cleared chronic Pseudomonas aeruginosa infections. ➡ The Phase 2b study will evaluate approximately XX patients over X weeks with topline results expected Q1 2026. ➡ BiomX's programs address unmet needs in diabetic foot osteomyelitis"  
![@MarketPulse360 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1517444811296587777.png) [@MarketPulse360](/creator/x/MarketPulse360) on [X](/post/tweet/1946259910141804881) 2025-07-18 17:24:56 UTC XX followers, XX engagements


"Netflix starts using GenAI in its shows and films"  
![@MarketPulse360 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1517444811296587777.png) [@MarketPulse360](/creator/x/MarketPulse360) on [X](/post/tweet/1946317127645847848) 2025-07-18 21:12:18 UTC XX followers, X engagements


"$PTNT Oral MC4R Agonist PL7737 Shows Positive Preclinical Data in Obesity Model ➡ According to the announcement Palatin Technologies' oral MC4R agonist PL7737 demonstrated significant weight loss in preclinical studies using a diet-induced obese rat model. ➡ Monotherapy with oral PL7737 resulted in rapid weight loss with a high dose achieving XX% weight loss after just X days of treatment based on the announcement. ➡ The combination of oral PL7737 and tirzepatide showed additive effects leading to a XX% weight loss with the high dose combination according to the announcement. ➡ Palatin is"  
![@MarketPulse360 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1517444811296587777.png) [@MarketPulse360](/creator/x/MarketPulse360) on [X](/post/tweet/1945091851066695844) 2025-07-15 12:03:30 UTC XX followers, XX engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@MarketPulse360 "Inspira Technologies Regains Nasdaq Compliance: Minimum Bid Price Achieved $IINN ➡ Inspira Technologies received notification from Nasdaq confirming compliance with the minimum bid price requirement. ➡ The company's common shares maintained a closing bid price at or above $XXXX per share for XX consecutive business days. ➡ According to the announcement Inspira's CEO Dagi Ben-Noon views this compliance as a reflection of market confidence in the company's strategic direction. ➡ Inspira is focusing on global distribution and execution leveraging achievements like a large commercial order and"
@MarketPulse360 Avatar @MarketPulse360 on X 2025-07-18 12:58:56 UTC XX followers, XX engagements

"Dr. Reddy's Launches Sanofi's Beyfortus in India for RSV Prevention #DRREDDY $RDY ➡ Dr. Reddys Laboratories has launched Beyfortus (nirsevimab) in India a preventive treatment for Respiratory Syncytial Virus (RSV) in infants following an expanded partnership with Sanofi. ➡ RSV is a significant yet underreported health crisis in India causing many respiratory infections in infants with experts reporting over 2000 child deaths in 2024 from Kolkata Bengaluru and Mumbai alone. ➡ According to the Article Beyfortus launch aligns with Dr. Reddy's dual-track growth strategy strengthening its core"
@MarketPulse360 Avatar @MarketPulse360 on X 2025-07-17 22:14:56 UTC XX followers, XX engagements

"BiomX's Phase 2b Trial Begins Analyst Reiterates $XX Target $PHGE ➡ BiomX initiated patient dosing in Phase 2b trial for BX004 targeting lung infections in cystic fibrosis patients. ➡ H.C. Wainwright reaffirmed a Buy rating and $XX price target for BiomX citing confidence in its dual-asset approach. ➡ Phase 1b/2a trial of BX004 showed XXXX% of patients completely cleared chronic Pseudomonas aeruginosa infections. ➡ The Phase 2b study will evaluate approximately XX patients over X weeks with topline results expected Q1 2026. ➡ BiomX's programs address unmet needs in diabetic foot osteomyelitis"
@MarketPulse360 Avatar @MarketPulse360 on X 2025-07-18 17:24:56 UTC XX followers, XX engagements

"Netflix starts using GenAI in its shows and films"
@MarketPulse360 Avatar @MarketPulse360 on X 2025-07-18 21:12:18 UTC XX followers, X engagements

"$PTNT Oral MC4R Agonist PL7737 Shows Positive Preclinical Data in Obesity Model ➡ According to the announcement Palatin Technologies' oral MC4R agonist PL7737 demonstrated significant weight loss in preclinical studies using a diet-induced obese rat model. ➡ Monotherapy with oral PL7737 resulted in rapid weight loss with a high dose achieving XX% weight loss after just X days of treatment based on the announcement. ➡ The combination of oral PL7737 and tirzepatide showed additive effects leading to a XX% weight loss with the high dose combination according to the announcement. ➡ Palatin is"
@MarketPulse360 Avatar @MarketPulse360 on X 2025-07-15 12:03:30 UTC XX followers, XX engagements

creator/twitter::1517444811296587777/posts
/creator/twitter::1517444811296587777/posts